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We previously demonstrated that the transcription factor Pax4 is important for b-cell replication and survival
in rat islets. Herein, we investigate Pax4 expression in islets of non-diabetic and diabetic donors, its regu-
lation by mitogens, glucose and the incretin GLP-1 and evaluate its effect on human islet proliferation.
Pax4 expression was increased in islets derived from Type 2 diabetic donors correlating with hyperglycae-
mia. In vitro studies on non diabetic islets demonstrated that glucose, betacellulin, activin A, GLP-1 and insu-
lin increased Pax4 mRNA levels. Glucose-induced Pax4 expression was abolished by the inhibitors
LY294002, PD98050 or H89. Surprisingly, increases in Pax4 expression did not prompt a surge in human
islet cell replication. Furthermore, expression of the proliferation marker gene Id2 remained unaltered.
Adenoviral-mediated expression of human Pax4 resulted in a small increase in Bcl-xL expression while Id2
transcript levels and cell replication were unchanged in human islets. In contrast, overexpression of
mouse Pax4 induced human islet cell proliferation. Treatment of islets with 5-Aza-20-deoxycytidine induced
Pax4 without stimulating Bcl-xL and Id2 expression. Human Pax4 DNA binding activity was found to be
lower than that of the mouse homologue. Thus, human pax4 gene expression is epigenetically regulated
and induced by physiological stimuli through the concerted action of multiple signalling pathways.
However, it is unable to initiate the transcriptional replication program likely due to post-translational modi-
fications of the protein. The latter highlights fundamental differences between human and rodent islet physi-
ology and emphasizes the importance of validating results obtained with animal models in human tissues.
INTRODUCTION
The ultimate goal in the management of diabetes is to achieve
optimal glucose control while avoiding hypoglycaemia.
Human islet transplantation has provided proof of principle
that it is feasible to partially normalize blood glucose in
Type 1 diabetic patients (1). However, this approach is
severely hampered by the shortage of donor pancreata and
thus alternative sources of cells as well as protocols are
required to generate new surrogate b-cells. The encouraging,
yet controversial results obtained to date with either embryonic
or adult stem cells, necessitate re-evaluation of approaches to
be taken in order to produce safe and fully differentiated
insulin-producing cells in vitro (2). More recently, in vivo
cell regeneration has gained attention with the finding that
residual b-cells are detected in long standing Type 1 diabetic
patients (3,4). Consistent with the latter, we and others have
proposed that b-cells can replicate and most likely constitute
the main venue of cell regeneration under physiological con-
ditions (5–8). Harnessing signals and factors involved in con-
trolling b-cell replication to restore glucose homeostasis in
Type 1 diabetic patients would circumvent the need for
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insulin therapy or invasive surgery. Individuals with Type 2
diabetes would also benefit from agents that protect or
expand b-cell mass, as several studies have clearly demon-
strated a significant decrease in insulin-producing cells in
these patients (9,10).
Of particular interest is the b-cell transcription factor Pax4
for which polymorphisms and mutations have been associated
with Types 1 and 2 diabetes, respectively (11–17). Consistent
with the oncogenic function of other pax genes in human
cancer (18), we have demonstrated that Pax4 is a key regulator
of b-cell plasticity (5). Mitogens such as activin A or betacel-
lulin induced Pax4 expression with a concomitant increase in
rat b-cell replication. Overexpression of murine Pax4 in rat as
well as in human islets induced b-cell proliferation and con-
ferred protection against cytokine-induced apoptosis. These
beneficial effects were conveyed by increased Bcl-xL (an anti-
apoptotic gene), c-myc (a proto-oncogene) and Id2 (a c-myc
target gene) mRNA levels in rat islets (5). Similarly, the pur-
ified recombinant Pax4 protein was recently found to permeate
into human cell lines as well as pancreatic islets and sub-
sequently activate Bcl-xL and c-myc (19). Interestingly, low
concentrations of IL-1b induced both endogenous Pax4 tran-
scription and b-cell proliferation whereas high levels of the
cytokine inhibited expression of the transcription factor and
induced apoptosis in human islets (20). The latter findings
indicate an initial beneficial effect of cytokines on islet mass
whereas higher levels become detrimental, a phenomenon
potentially mimicking the in vivo conditions of both Types 1
and 2 diabetic patients (21).
Although our previous studies clearly indicate that Pax4 is
an important molecular mediator relaying physiological cues
to islet mass adaptation, no data on the effects of endogenous
Pax4 on human islet cell proliferation are available. Therefore,
in the present study, we investigated the expression of Pax4 in
islets of non-diabetic and diabetic patients, its regulation by
mitogens, glucose and the incretin GLP-1 as well as evaluating
its effect on cell replication.
RESULTS
Pax4 is expressed in human pancreatic islets
and is increased in Type 2 diabetic patients with BMI
between 22 and 26
In order to determine whether Pax4 expression was modulated
in pathophysiological conditions such as hyperglycaemia and/
or obesity, Pax4 transcript levels were evaluated in islets
freshly isolated from a small cohort of Type 2 diabetic
donors and related to body mass index (BMI). Pax4 transcript
was detected in human islets and increased 10-fold in diabetic
donors with a BMI between 22 and 26 when compared with
control non-diabetic donors (Fig. 1; 5.7+ 2.8 versus 0.5+
0.1, P, 0.05). In contrast to BMI, no correlation between
Pax4 mRNA levels and age or sex could be established.
Although few donors were analysed, no changes in Pax4
mRNA levels were detected in either group with BMI
greater than 26. Noteworthy, control islets exhibited astonish-
ingly small variations in Pax4 mRNA levels independent of
BMI. These results suggest that hyperglycaemia is most
likely sufficient to induce Pax4 expression in Type 2 diabetic
donors whereas long-term adiposity appears to favour suppres-
sion of the gene.
To determine whether development of Type 2 diabetes in
donors with increased levels of Pax4 could be potentially cor-
related to polymorphisms and/or mutations associated with the
disease (12–15,17), DNA isolated from seven donors (four
diabetics and three non-diabetics) were sequenced in regions
of interests in the pax4 gene. Individual diabetes-linked poly-
morphisms or mutations could not be identified within the
paired domain of the pax4 gene (data not shown). Interest-
ingly, three of the four Type 2 diabetic donors as well as
two of the three non-diabetic donors carried a previously
described single nucleotide polymorphism (SNP rs698406; G
to C) at position 1298 (relative to the transcriptional initiation
site). This SNP is located within intron 3 and has not yet been
assigned any functional phenotype.
Glucose-induced insulin release stimulates Pax4 gene
transcription in human islets
To validate the hypothesis that glucose is responsible for the
in vivo up-regulation of Pax4 expression, primary culture of
human control islets were exposed to increasing concen-
trations of glucose for 24 and 48 h. A 3-fold increase in
Pax4 mRNA levels was observed in islets treated with
25 mM glucose, whereas transcript levels returned to basal
values at 33 mM glucose (Fig. 2A). No significant differences
in the induction of Pax4 expression were observed between 24
and 48 h. Correspondingly, Ipf1 mRNA levels also exhibited a
bell-shape expression pattern reaching maximal induction of
approximately 2-fold at 25 mM glucose before decreasing to
basal levels at 33 mM glucose. We have previously demon-
strated that low concentrations of IL-1b via the FAS-FLIP sig-
nalling pathway induced Pax4 expression, whereas high
concentrations inhibited mRNA levels of the transcription
factor (20). Corroborating these studies, we found that
Figure 1. Pax4 mRNA expression levels are increased in human islets isolated
from Type 2 diabetic donors with BMI between 22 and 26. Pax4 expression
was measured by quantitative RT–PCR in isolated pancreatic islets from
(B) T2DM (7 males and 6 females) and (D) non-diabetic control donors (6
males and 2 females). The average age of donors was 64+10 years
(48,age.80). Data are presented as relative mRNA abundance levels nor-
malized to the housekeeping gene transcript cyclophilin levels in function of
body mass index (BMI). Each dot represents an individual donor.
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glucose dose dependently induced IL-1b and FAS transcript
levels reaching maximal induction of 5- and 3-fold, respect-
ively, at 33 mM glucose whereas the expression pattern of
the caspase-8 inhibitor FLIP mimicked that of Pax4
(Fig. 2C). These results suggest that islets exposed to elevated
glucose concentrations such as in Type 2 diabetic patients will
produce increasing amounts of IL1-b and FAS ultimately inhi-
biting pax4 gene transcription and induce cell death (20).
As the predominant function of glucose metabolism in
b-cells is to promote insulin secretion which may then have
an autocrine effect on islet cells, we investigated whether
insulin could stimulate Pax4 expression. Addition of exogen-
ous insulin in the presence of 5.6 mM glucose prompt a
3.5-fold increase in Pax4 mRNA levels when compared with
control islets whereas Ipf1 levels remained constant (Fig. 2D
and E). Addition of diazoxide, a KATP channel opener which
blocks nutrient-induced insulin secretion, completely abro-
gated the effect of 15 mM glucose on Pax4 as well as on
Ipf1 expression (Fig. 2D and E). Taken together our data
suggests that most likely insulin released in response to high
glucose is the main stimulator of Pax4 transcription. In con-
trast, glucose and not insulin appears to be the main stimulator
of Ipf1 transcription in human islets (22).
Pax4 expression in human islets is induced by activin A,
betacellulin and GLP-1
In order to determine whether other growth factors stimulated
pax4 gene expression, human islets were cultured in the pre-
sence of either activin A (a member of the TGF-b family)
or betacellulin (a member of the EGF family). Pax4 mRNA
levels were increased by approximately 5-fold in islets
treated with either 0.5 nM activin A or betacellulin for 24 or
48 h (Fig. 3A). Interestingly, the combination of activin A
and betacellulin in the presence of either 5.6 or 15 mM
glucose did not further increase Pax4 expression when
Figure 2. Glucose stimulates Pax4 gene expression in isolated human islets. (A) Pax4, (B) Ipf1, (C) IL-1b, Fas and FLIP mRNA levels in islets treated with
increasing doses of glucose as indicated in the figure legends. Quantitative RT–PCR using RNA purified from cultured human islets was performed on Pax4 and
the mentioned genes. Data are presented as fold change of mRNA levels when compared with 5.6 mM Glc normalized to the cyclophilin transcript. Values rep-
resent the mean+SEM of 3–5 independent experiments performed in duplicates. (D and E) Islets were incubated with 5.6 mM Glc in the absence or presence of
insulin (50 nM) or with 15 mM Glc in the absence or presence of the non-selective KATP channel opener diazoxide (250 mM). (D) Pax4 and (E) Ipf1 transcripts
abundance levels were estimated by quantitative RT–PCR. Statistical significance was tested by Student’s t-test. P, 0.05; P, 0.01.
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compared with individual mitogens (data not shown). As in rat
islets (5), TGF-b1 had no consequence on Pax4 expression.
Ipf1 mRNA levels were not significantly increased by
activin A, betacellulin or TGF-b1 treatments (Fig. 3B). We
next determine the impact of GLP-1, a new therapeutic
agent for the treatment of diabetes which has been shown to
increase b-cell mass in mouse and rat pancreas as well as pro-
moting cell proliferation in INS-1 cells (23–27). GLP-1
(10 nM) in combination with 5.6 mM glucose had no stimu-
latory effect while in the presence of 15 mM glucose the incre-
tin elicited a 6-fold increase in Pax4 mRNA levels at either 24
or 48 h (Fig. 3C). This increase was significantly greater than
that of 15 mM glucose alone at 24 h indicating that GLP-1
potentiated the effect of the sugar on Pax4 stimulation.
Similar results were obtained with the long acting analogue
of GLP-1, exendin-4 (data not shown).
Investigation as to which particular secondary signal might
evoke an increase in Pax4 expression in response to glucose
alone or in combination with the incretin was then conducted.
Inhibition of the PI3K pathway with LY294002 repressed both
glucose and glucose/GLP-1-mediated increase in Pax4
expression (Fig. 3E). Likewise, Pax4 induction was comple-
tely blunted by the MEK1/2 specific inhibitor PD98059
which blocks the ERK1/2 axis of the insulin signalling
pathway (Fig. 3E). To determine the contribution of the
cAMP-PKA pathway in the stimulation of Pax4 expression,
islets cultured in the presence of 15 mM glucose with or
without of GLP-1 were treated with the PKA inhibitor H89.
Induction of Pax4 expression was abrogated in the presence
of H89 (Fig. 3E). Taken together, these results indicate that
glucose most likely via insulin enhance Pax4 expression
through activation of both the ERK1/2 and PI3K branches of
the insulin signalling cascade as well as the cAMP-PKA
pathway. As cross talk between these three pathways has pre-
viously been established (28), incapacitating any one cascade
results in complete inhibition of Pax4. Complete inhibition of
Figure 3. Activin A, betacellulin and the incretin GLP-1, in combination with glucose, increase Pax4 mRNA levels in human islets. (A) Pax4 and (B) Ipf1
mRNA levels in islets treated with activin A, betacellulin or TGF-ß1 as indicated in the figure legend. Quantitative RT–PCR analysis was performed as described
in Figure 2. (C) Pax4 and (D) Ipf1 mRNA levels in islets incubated with glucose in the absence or presence of GLP-1 (10 nM), as indicated on the graph. (E)
Pax4 and (F) Ipf1 mRNA levels in islets incubated with glucose, GLP-1, the PI3-kinase inhibitor LY294002, the MEK1/2 specific inhibitor PD98059 and the
PKA-specific inhibitor H89, as indicated on the graph. The results are normalized to cyclophilin and are expressed as fold change of mRNA when compared with
control. Data are expressed as the mean+SEM of four independent experiments. P , 0.05; P , 0.01.
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the stimulatory effect of GLP-1 in combination with 15 mM
glucose on Pax4 expression confirms the strict dependency
of the incretin action on the presence of the sugar.
Surprisingly, glucose-mediated stimulation of Ipf1 expression
was not further increased by the addition ofGLP-1 (Fig. 3F). Fur-
thermore, PD98059 and H89 but not LY294002 inhibited induc-
tion of Ipf1 expression by glucose indicating that, in contrast to
Pax4, stimulation of Ipf1 is not dependent on the PI3K pathway.
Mitogens and GLP-1-mediated activation of endogenous
Pax4 does not increase human b-cell proliferation
We have previously demonstrated that stimulation of pax4 gene
expression by activin A and betacellulin coincided with rat islet
cell proliferation (5). In parallel, GLP-1 was previously shown
to stimulate rodent and murine b-cell replication (29,30). Thus,
to determine whether mitogens- and GLP-1-elicited increases
in Pax4 expression levels correlated with induction of human
islet cell replication, BrdU-incorporation was evaluated in
islets treated with various growth factors. Consistent with a pre-
vious study, we found that the total number of islet cells under-
going proliferation under non-stimulatory conditions was
0.5% (Fig. 4A) (31). Astonishingly, addition of activin A,
betacellulin or GLP-1 failed to induce replication (Fig. 4A).
Longer incubation time in the presence of BrdU and growth
factors (alone or in combination) as well as culturing cells on
various substrata (up to 6 days) did not improve yield of
labelled cells (data not shown). In contrast, rat islets exposed
to GLP-1 or activin A displayed a 2.5-fold increase in BrdU-
labelling while betacellulin elicited a 3-fold increase when
compared with control 5.6 mM treated islets (Fig. 4B).
To address the possibility that human islet b-cells are refrac-
tory to these physiological stimuli in vitro, we investigated
whether nuclear translocation of the proliferation marker Id2
(32,33) occurred in activin A treated islets. As expected, under
control conditions Id2 was predominantly localized to the cyto-
plasm of both human and rat islet cells, whereas addition of
activin A prompted nuclear translocation of the protein
(Fig. 4C and D). Interestingly, translocation was only observed
in b-cells despite presence of Id2 in all cell types. These
results suggest that human b-cells are responsive to mitogens
such activin A resulting in Pax4 stimulation and Id2 nuclear
translocation but fail to subsequently enter into the S-phase.
Human islet proliferation is not significantly induced by
adenoviral-mediated overexpression of human Pax4
In order to investigate whether supra-physiological levels of
human Pax4 could force entry of cells into the replication
phase, human islets were infected with a doxycycline induci-
ble adenoviral construct bearing the human Pax4 cDNA
tagged with a myc epitope. The latter was essential to
reveal Pax4 by immunocytochemistry as no reliable antibodies
for the transcription factor are commercially available. A
14-fold increase in Pax4 transcript levels was estimated sub-
sequent to doxycycline treatment corresponding to a 2-fold
increment when compared with islets incubated with activin
A or betacellulin (compare Fig. 5A to 3A). Consistent with
our previous studies in rat islets (5), overexpression of Pax4
did not alter Ipf1 mRNA levels. Interestingly, a small but
significant 1.6-fold increase in transcript levels of the
Pax4-target gene, Bcl-xL was found in doxycycline treated
islets whereas Id2 mRNA levels maintained basal values
when compared with untreated islets (Fig. 5B). The latter
results would tend to suggest that human Pax4, in contrast to
the mouse variant (5), is less efficient in activating downstream
target genes and thus to stimulate proliferation. Consistent with
this hypothesis, immunocytochemistry revealed that although
Pax4 was expressed in 60% of cell nuclei after doxycycline
treatment (Fig. 5C), no significant increase in BrdU labelling
could be discerned when compared with control untreated
islets (Fig. 5D and E). In contrast, human islets transduced
with the mouse variant of Pax4 employing the same viral trans-
duction system, displayed a 10-fold increase in islet cell replica-
tion (Fig. 5F). As an activator and/or repressor domain was
previously identified at the carboxy-terminal end of Pax4
(34), we investigated whether activin Amay be required to acti-
vate the transcription factor and increase proliferation in trans-
duced islets. No further increase in BrdU labelling was
discerned in these islets when compared with non-induced
Ad-hPax4-myc-infected islets (Fig. 5E). Similar attempts to
stimulate proliferation in the presence of betacellulin and
GLP-1 also failed (data not shown).
We next evaluated the capacity of both the human and mouse
Pax4 to promote cell replication in rat islets. Subsequent to
infection and doxycycline treatment, 70% of islet cells
expressed either recombinant protein (Fig. 6A). However, simi-
larly to human islets, only mouse Pax4 was capable of stimulat-
ing proliferation suggesting potential post translational
modifications of the human protein that modulates its activity.
Pax4 gene expression in human and rat islets
is regulated by epigenetic modifications
Aberrant DNA demethylation in the pax4 gene promoter was
recently shown to induce expression of the transcription factor
in lymphocytes and promote haematologic malignancies (35).
Furthermore, a member of the id gene family, Id4 was also
found to be regulated by epigenetic modifications (36).
These findings suggest that Pax4 expression as well as down-
stream target genes may be epigenetically regulated in human
islets thereby blocking activation of the replication program.
Consistent with this premise, human islets treated with
increasing concentrations of the DNA methyltransferase
inhibitor, 5-Aza-20-deoxycytidine (50-AZA) for 72 h exhibited
a gradual increase in Pax4 mRNA levels reaching maximal
induction of 3-fold with 20 mM of the drug (Fig. 7A). In con-
trast, Ipf1 mRNA levels were unaltered. Nonetheless, neither
Bcl-xL nor Id2 gene expression was increased in the presence
of 50-AZA (Fig. 7B). In contrast, a 10-fold stimulation in Pax4
transcript levels as well as a concomitant increase of 2.5- and
3-fold in Id2 and Bcl-xL gene expression was observed in rat
islets incubated with 10 mM 50-AZA (Fig. 7C and D). These
results highlight a novel regulatory mechanism of pax4 gene
expression through epigenetic modification in rat and human
islets. However, alleviation of this regulatory checkpoint was
still not sufficient to activate downstream target genes. The
latter conclusion combined with the adenoviral transduction
studies showing a modest increase in only Bcl-xL transcript
in the presence of supra physiological levels of human Pax4,
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prompt us to investigate whether the human Pax4 protein
when compared with the rat or mouse variant might be less
efficient in trans-activating target genes. Electrophoretic
mobility shift assays (EMSAs) using equal amounts of recom-
binant mouse and human Pax4 (Fig. 7F) revealed a much
stronger binding of the mouse variant to the glucagon gene
promoter element G3 (Fig. 7E) when compared with the
human protein. The latter therefore substantiates the concept
that the human protein is a poor trans-activator and requires
much higher levels than its murine counterpart to stimulate
transcription and most likely proliferation.
DISCUSSION
The beneficial effect of Pax4 on b-cell replication and survival
has been well established in rodent islets. A similar positive
outcome was also demonstrated in human islets in which
murine Pax4 was overexpressed using adenovirus (5).
However, regulation of endogenous pax4 gene as well as its
functional role in human islet plasticity under physiological
or pathophysiological conditions remains obscure. Herein we
show that islets derived from Type 2 diabetic donors with
BMI between 22 and 26 have elevated levels of Pax4 tran-
script when compared with non-diabetic controls whereas
expression levels are indistinguishable between the two
groups with BMI greater than 26. Previous work reported a
slight increase in Pax4 expression in Type 2 diabetes islets
relative to controls (37). The relatively stable expression
level of Pax4 in non-diabetic patients across BMI values
suggests that hyperglycaemia acts as an important inducer of
Pax4 expression and potentially cell replication in diabetic
islets. Consistent with this premise, Pax4 expression was
Figure 4. Activin A, betacellulin or GLP-1 do not induce human b-cell proliferation. Islet cell proliferation was measured by BrdU incorporation in (A) human
and (B) rat islets treated with the indicated growth factors for 4 days. Dispersed islet-cells immunostained for BrdU were counted under a fluorescent microscope
and results are depicted as a percentage of BrdU positive cells over the total amount of cells identified by DAPI staining. Data represent the mean+SE of 4
independent experiments, each representing more than 1000 cells per condition. P , 0.05, P , 0.01. (C–D) The downstream target of Pax4, Id2 is expressed
in the cytoplasm of human and rat islets and translocates to the nucleus of b-cells in the presence of activin A (0.5 nM). Immunofluorescent detection of Id2
(green), insulin (red) as well as DAPI nuclei staining (blue) in dispersed human (C) and rat (D) islet cells incubated in the absence or presence of activin A
(0.5 nM) for 48 h. The merge image of the Id2 and insulin is shown. Bars, 50 mm.
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stimulated in human islets cultured in either 11 or 25 mM
glucose while transcript levels returned to basal levels with
higher concentrations. A similar bell-shaped Pax4 expression
pattern was reported in human islets cultured with increasing
concentrations of Il-1b. Indeed, low concentrations of the
cytokine correlated with enhanced Pax4 expression and
improved islet function whereas high levels inhibited Pax4
and induced apoptosis (20). In the current study, we
show that Il-1b and its downstream target FAS were
dose-dependently increased by glucose. It is therefore tempt-
ing to speculate that initial increases in Pax4 expression
detected in human diabetic islets could be partly conveyed
by glucose-induced Il-1b generation and release, whereas
chronic exposure to the cytokine becomes inhibitory and det-
rimental to cells. The latter would also corroborate with the
observation that Type 2 diabetic islets expressed the cytokine
as a result of hyperglycaemia (38). We also demonstrate that
insulin released in response to high glucose plays a pivotal
Figure 5. Adenoviral-mediated overexpression of human Pax4 does not stimulate replication in human islets. Islets were co-infected with Ad-hPax4-myc or
Ad-mousePax4-myc along with Ad-X Tet-On as described in Materials and Methods. Doxycycline-dependent activation of human PAX4 was then assessed
48 h later by (A) quantitative RT–PCR and (C) immunohistochemistry; myc epitope (red), insulin (green) and DAPI (blue). Pax4 was detected via the myc
epitope in the nuclei of 60% of human islet cells cultured in the presence of doxycycline (0.5 mg/ml), while no basal induction of Pax4 was observed in
the absence of doxycycline. Bars, 50 mm. (B) Bcl-xL and Id2 transcript levels in Ad-hPax4-myc transduced islets incubated with or without doxycycline.
Each value represents mean+SEM of 5 independent experiments. Islet cell proliferation was measured by BrdU incorporation in human islets infected with
(D and E) Ad-hPax4-myc or with (F) Ad-mousePax4-myc and cultured with (0.5 mg/ml) or without doxycycline and activin A (0.5 nM) in the presence of
BrdU (10 mM) for 4 days. (D) Islets were immunostained for BrdU (red), insulin (green) and DAPI (blue). Bars, 50 mm. (E–F) Dispersed islet cells immunos-
tained for BrdU were counted under a fluorescent microscope and results are depicted as a percentage of BrdU positive cells over the total amount of cells as
determined by DAPI staining. Data show the mean+SE of 5–6 independent experiments, each representing more than 1000 cells per condition. P , 0.05;
P , 0.01.
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role in stimulating Pax4 expression. The latter correlates with
recent findings showing that exogenous insulin protected
human islets from apoptosis induced by serum withdrawal
(22). Interestingly, islets of Type 2 diabetic donors with
BMI values greater than 26 exhibited Pax4 mRNA levels iden-
tical to those of non-diabetic islets suggesting that adiposity
may repress hyperglycaemia-induced Pax4 expression. Of
note, palmitate known to be elevated in plasma of obese indi-
viduals, has been reported to attenuate human b-cell prolifer-
ation (39). Moreover, prolonged exposure to free fatty acids
induced b-cell apoptosis in human islets (40). The current
data thus suggest a causal association between the expression
pattern of endogenous Pax4 and dynamic alterations observed
in b-cell mass in response to hyperglycaemia.
Similar to rat islets, activin A and betacellulin increased
Pax4 expression in human islets (5). However, this stimulation
was approximately 2-fold lower in magnitude to that observed
in rat islets. Interestingly, an analogous diminished response to
glucose was also apparent comparing human and rat islets (this
study and reviewed in 41). Taken together, human islets
appear more resistant to growth factors. The latter does not
emerge from an in vitro artefact or an effect of donor
factors as human islets were shown to have improved function
in vivo subsequent to prolonged culture time (42,43).
However, we discovered that Pax4 expression was regulated
by epigenetic modification which may impose restriction on
the level of transcriptional activation by various stimuli in
human islets. It will be of interest to determine whether com-
bined treatment of islets with mitogens and 50-AZA induces
Pax4 expression to levels detected in rat islets. Addition of
GLP-1 to 15 mM glucose further increased Pax4 mRNA
levels indicating that the incretin potentiates the effect of
glucose. This induction was found to be dependent on
cAMP/PKA, ERK1/2 and PI3K activities suggesting that
extensive cross talk between the G-protein coupled receptor
and tyrosine coupled receptor transduction pathways is
taking place before converging onto Pax4. Consistent with
the premise that the effect of GLP-1 is glucose dependent,
all three inhibitors completely abrogated the glucose-mediated
stimulation of Pax4. Friedrichsen et al. (30) have recently
demonstrated that GLP-1 induced cyclinD1 gene transcription
in rat islets with the subsequent induction of b-cell replication.
Interestingly, the latter effects were completely blocked by the
inhibitors LY294002, PD98050 and H89. In an independent
study, adenoviral-overexpression of cyclin D1 in human
islets caused a 2.5-fold increase in thymidine incorporation
(31). Thus, it will be of interest to determine whether induc-
tion of cyclin D1 and proliferation by glucose and the incretin
is conveyed by Pax4.
Our data demonstrate that induction of Ipf1 expression was
refractory to activin A, betacellulin as well as TGF-b1. To our
knowledge, no studies have investigated the impact of these
mitogens on the regulation of Ipf1 in mature human islets.
However, conditional expression of Smad7 in mouse pancrea-
tic islets which disrupted the TGF-b signalling pathway had
no consequence on Pdx1 (mouse homologue of Ipf1) mRNA
levels (44) indicating that expression of the transcription
factor is not regulated by TGF signalling in either murine or
humans. Intriguingly, GLP-1 did not further stimulate Ipf1
expression induced by high glucose concentrations. This is
sharp contrast to a single study performed with human foetal
pancreas showing that Exendin-4 (a long-acting derivative of
GLP-1) up-regulated expression of Ipf1 and accelerated differ-
entiation and maturation of b-cells from precursor cells (45).
This apparent discrepancy may be reconciled by the premise
that Ipf1 expression during development may be regulated
by GLP-1 whereas in mature human islet ipf1 gene transcrip-
tion is refractory to the incretin. The irrefutable beneficial
impact of GLP-1 on b-cell function in human subjects could
still involve post-translational regulation of Ipf-1. In support
of this hypothesis, insulin was recently found to stimulate
Ipf1 nuclear translocation in human b-cells correlating with
decreased apoptosis (22).
An unexpected finding of the current study was the com-
plete absence of increased human islet proliferation by
activin A, betacellulin, glucose or GLP-1. Astonishingly,
very few studies have successfully demonstrated growth
factor-induced proliferation of adult human b-cells (reviewed
in 28) while the impact of GLP-1 on human islet mass expan-
sion remains to be established. A recent study demonstrated
that age of donor correlated with decreased proliferative
capacity of human b-cells which could account for our
inability to stimulate proliferation (46). However, stimulation
Figure 6. Adenoviral-mediated overexpression of human Pax4 does not stimu-
late replication in rat islets. Rat islets were co-infected with either
Ad-hPax4-myc or Ad-mousePax4-myc and Ad-X Tet-On as described in
Materials and Methods. Doxycycline-dependent activation of PAX4 was
then assessed 48 h later by (A) immunohistochemistry; myc epitope (green),
insulin (red) and DAPI (blue). Bars, 50 mm. (B) Islet cell proliferation was
measured by BrdU incorporation in rat islets infected with Ad-hPax4-myc
or with Ad-mousePax4-myc and cultured with (0.5 mg/ml) or without doxycy-
cline in the presence of BrdU (10 mM) for 4 days. Dispersed islet cells immu-
nostained for BrdU were counted and results are depicted as a percentage of
BrdU positive cells over the total amount of cells. Data show the mean+
SE of four independent experiments, each representing more than 800 cells
per condition. P , 0.01.
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of Pax4 expression and the concomitant nuclear translocation
of the proliferative marker Id2 by mitogens indicated that
growth factor-mediated signalling was functionally adequate
to set in motion the replication programme but that down-
stream activation of target genes was abortive and/or
blocked. Overexpression of human Pax4 confirmed this
assumption as Id2 expression was not induced while Bcl-xL
transcript levels were slightly increased in transduced human
islets. The failure of human Pax4 to stimulate downstream
target genes did not appear to stem from epigenetic modifi-
cation, as treatment with 50-AZA fail to induce expression of
either Bcl-xL or Id2 while Pax4 transcription was activated.
Interestingly, Pax4 as well as Id2 and Bcl-xL were strongly
induced subsequent to 50-AZA treatment of rat islets
suggesting that human Pax4 is less efficient in trans-activating
its downstream target genes. This premise was confirmed by
EMSA studies and substantiated a previous study showing
weak interaction of the human Pax4 protein with its cognate
DNA binding sequence when compared with the mouse
protein (14). The latter results thus reconcile the observation
that overexpression of mouse but not human Pax4 in either
human or rat islets was capable of inducing cell replication.
The question arises as why rodent Pax4 is a more robust trans-
activator when compared with its human counterpart. Align-
ment of the three proteins revealed an 89% similarity in the
DNA binding domains whereas a 50% amino acid divergence
was estimated in the carboxy-terminal end (amino acids 230–
352) of the rat and mouse sequence to that of the human. This
segment of the transcription factor was previously shown to
contain a repressor/trans-activator domain (34,47). Interest-
ingly, human insulinomas were shown to contain high levels
of a Pax4 variant lacking the carboxy-terminal end of the
protein (48). It is therefore tempting to speculate that a
nuclear co-factor interacts with the carboxy-terminal end of
the human protein regulating DNA binding. This possibility
is currently being explored with the use of chimeras containing
the amino-terminal end of the human Pax4 linked to the
carboxy-terminal end of the mouse protein and the reverse.
Figure 7. Inhibition of DNA methylase induces Pax4 gene expression in human and rat islets. Isolated (A and B) human and (C and D) rat islets were treated
with increasing concentrations of the DNA methyltransferase inhibitor, 50-Aza-20-deoxycytydine (50-AZA) for 72 h. Pax4, Ipf1/Pdx1, Bcl-xL and Id2 transcripts
abundance levels were estimated by quantitative RT–PCR. Data are presented as fold change of mRNA levels when compared with control islets normalized to
cyclophilin and represent the mean+SEM of at least three independent experiments performed in duplicates.P , 0.05; P, 0.01. (E) EMSA using the radio-
labelled G3 element of the glucagon gene promoter and the recombinant proteins mouse and human Pax4-myc. An equal amount of protein was applied in each
lane (Fig. 6F). Mouse Pax4 bound strongly to the G3 element whereas the binding of the human Pax4 was less efficient. (F) Western blotting of the recombinant
proteins mouse and human Pax4-myc using an anti myc epitope antibody. The same anti-myc serum was used for Western blotting and immunofluorescence.
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Alternatively, phosphorylation of serine/threonine residues in
this region may also regulate binding activity has previously
demonstrated for Pdx1 and NeuroD (49,50).
In summary, this study demonstrates that Pax4 expression is
increased in Type 2 diabetic donor islets, an effect which is
mediated by high circulating blood glucose and inhibited by
increased adiposity. The latter is consistent with the hypoth-
esis that human islet b-cell mass initially expands to compen-
sate for insulin resistance but that there is a long-term failure
and development of Type 2 diabetes (51). Consistent with
these in vivo findings, we show that Pax4 expression is stimu-
lated in human islets cultured in the presence of mitogens,
glucose, insulin and GLP-1. However, due to potential func-
tional divergence in the human and murine Pax4 protein,
b-cell replication was not induced under any experimental
conditions. The latter highlights the fundamental differences
between human and murine/rodent islet physiology and
emphasizes the importance of validating results obtained
with animal models in human tissues. This dichotomy is
further reinforced by recent findings showing that cdk-4
which is essential for murine b-cell replication in totally
absent in human islets (52). Thus, elucidating the mechanism
by which the activity of the human Pax4 is restrained should
facilitate the development of a regenerative therapy for the
treatment of diabetes.
MATERIALS AND METHODS
Cell culture
Pancreatic islets were isolated from 7-week-old male Wistar
rats (Elevage Janvier, Le Genest-St-Isle, France) by collagen-
ase digestion (53), handpicked and cultured for 24 h in
11.5 mM glucose/RPMI-1640 supplemented with, 100 Units/
ml penicillin, 100 mg/ml streptomycin and 100 mg/ml genta-
mycin (Sigma-Aldrich, Basel, Switzerland). Freshly isolated
human islets were obtained from either the Cell Isolation
and Transplantation Laboratory in Geneva or from Ulm Uni-
versity in Ulm and maintained in CMRL-1066 (at 5.6 mM
glucose) supplemented with 10% FCS, 100 Units/ml penicil-
lin, 100 mg/ml streptomycin and 100 mg/ml gentamycin for
24 h. Subsequently, human islets were cultured for 24 and
48 h in the presence of increasing concentrations of glucose
(5.6, 11, 25 and 33 mM) with or without 10 nM GLP-1 or
250 mM diazoxide. In some instances, 20 mM LY294002
(PI3-kinase inhibitor), 20 mM PD98050 (MAPKK inhibitor)
or 10 mM H89 (PKA inhibitor) were individually added to
the culture media. Islets were also exposed to 50 nM insulin,
0.5 nM betacellulin (BTC), activin A, TGF-b1 or increasing
concentrations of 50-Aza-20-deoxycytidine. All chemicals
were purchased from Sigma-Aldrich.
Additionally, islets from Type 2 diabetic donors were iso-
lated at the Metabolic Unit at the University of Pisa as pre-
viously described (54) and processed for RNA extraction
(see below).
Adenoviral constructions
The human full length Pax4 cDNA was amplified from
human islet-derived RNA and initially cloned into the
pcDNA3.1/myc-His expression vector (Invitrogen, Basel,
Switzerland). Subsequently, the Pax4-myc DNA fragment
was subcloned into the pTRE-Shuttle2 vector (Takara Bio
Europe, St-Germain-en-Laye, France). The inducible cassette
was then transferred into the Adeno-X viral DNA to generate
the recombinant adenovirus Ad-hPax4-myc. The mouse Pax4
cDNA viral construct, Ad-mPax4-myc, was previously
described in (5).
Adenoviral infection of islets
Human or rat islets were co-infected with either
Ad-hPax4-myc or Ad-mPax4-myc along with the adenoviral
construct harbouring the tetracycline transcriptional activator
(Ad-X Tet-On) at a ratio of 2:1 (3.6  107 pfu/ml total viral
particles). Islets were rinsed 90 minutes post infection and cul-
tured in fresh media with or without 0.5 mg doxycycline.
Quantitative real time-PCR (QT-RT-PCR)
Total RNA from 50 islets was extracted using the Trizol
reagent (Invitrogen) and 2 mg were converted into cDNA as
previously described (55). Primers for cyclophilin, Id2,
Bcl-xL, IL-1b, Fas, FLIP, iNOS and Pax4 were designed
using the Primer Express Software (Applera Europe, Rotkreuz,
Switzerland) and sequences can be obtained on the Web page
of the corresponding author (http://phym.unige.ch/groupes/
gauthier/index.php). QT-RT-PCR was performed using an
ABI 7000 Sequence Detection System (Applera Europe) and
PCR products were quantified using the SYBR Green Core
Reagent kit (53). Two distinct amplifications derived from at
least 3 independent experiments were performed in duplicate
for each transcript and mean values were normalized to the
mean value of the reference mRNA cyclophilin. Authenticity
of each amplicon was verified by DNA sequencing.
Immunohistochemistry
Subsequent to treatment, islet single cell suspensions were
obtained using trypsin and concentrated on glass cover slips
by cytocentrifugation. Cells were washed with PBS and
fixed in 4% paraformaldehyde in PBS for 20 min at room
temperature. Mouse and human recombinant Pax4 myc
tagged proteins were visualized by immunohistochemistry
using an antibody against the myc epitope (dilution 1:200;
Invitrogen). Immunochemical detection of Id2 was performed
using a rabbit anti-human polyclonal antibody (dilution 1:200,
Santa Cruz, USA) while insulin immunostaining was per-
formed as previously described (56). Nuclei were then
stained with DAPI (10 mg/ml; Sigma). Cover slips were
mounted using DAKO fluorescent mounting medium and visu-
alized using a Zeiss Axiophot I.
Cell proliferation
Islets cultured in standard media containing 10% FCS and sup-
plemented with growth factors were labelled with 10 mM BrdU
for up to 6 days. Proliferation was estimated using an immuno-
histochemical assay kit as described by the manufacturer (BrdU
labelling and detection Kit, Roche Diagnostics, Switzerland).
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Results are expressed as the percentage of BrdU-positive cells
over the total amount of islet cells identified by nuclear DAPI
staining and are depicted as a BrdU labelling index.
Recombinant Pax4 preparation and electrophoretic
mobility shift assays (EMSAs)
EMSAs were performed as previously described (57) using an
oligonucleotide corresponding to the rat glucagon gene promo-
ter element G3 (58) along with either human or mouse recom-
binant Pax4 protein generated from an in vitro transcription and
translation system (Promega Inc., Wallisellen, Switzerland).
Western blotting
In vitro produced human and mouse recombinant Pax4 pro-
teins were resolved on a 10% SDS–polyacrylamide gel and
transferred to a PVDF membrane. The membrane was
blocked in 20 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1%
Tween-20, 5% milk powder and then incubated with a
myc-epitope antibody (Invitrogen). Immunoreactive products
were revealed by enhanced chemiluminescence (SuperSignal
West Pico, Pierce, Rockford, IL, USA) using horseradish per-
oxidase coupled secondary antibodies.
Statistical analysis
Results are expressed as mean + SEM. Where indicated, the
statistical significance of the differences between groups was
estimated by Student’s unpaired t-test.  and  indicate stat-
istical significance with P, 0.05 and P, 0.01, respectively.
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